Mok TS, Kim D, Wu Y, et al. Overall Survival (OS) for First-Line Crizotinib Versus Chemotherapy in ALK+ Lung Cancer: Updated Results from PROFILE 1014. ESMO 2017, abstract LBA50.
Veranderingen in HER2-expressie tussen primaire borsttumor en hersenmetastasen
jan 2025 | Borstkanker